- Home
- SNDX vs JBI Comparison
SNDX vs JBI Comparison
Compare SNDX & JBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- JBI
- Stock Information
- Founded
- SNDX 2005
- JBI 2002
- Country
- SNDX United States
- JBI United States
- Employees
- SNDX N/A
- JBI N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- JBI Building Products
- Sector
- SNDX Health Care
- JBI Industrials
- Exchange
- SNDX Nasdaq
- JBI Nasdaq
- Market Cap
- SNDX 1.1B
- JBI 924.6M
- IPO Year
- SNDX 2016
- JBI N/A
- Fundamental
- Price
- SNDX $9.48
- JBI $7.96
- Analyst Decision
- SNDX Strong Buy
- JBI Buy
- Analyst Count
- SNDX 11
- JBI 6
- Target Price
- SNDX $35.91
- JBI $9.80
- AVG Volume (30 Days)
- SNDX 1.8M
- JBI 1.3M
- Earning Date
- SNDX 07-31-2025
- JBI 08-06-2025
- Dividend Yield
- SNDX N/A
- JBI N/A
- EPS Growth
- SNDX N/A
- JBI N/A
- EPS
- SNDX N/A
- JBI 0.35
- Revenue
- SNDX $43,722,000.00
- JBI $919,800,000.00
- Revenue This Year
- SNDX $426.77
- JBI N/A
- Revenue Next Year
- SNDX $98.31
- JBI $5.69
- P/E Ratio
- SNDX N/A
- JBI $22.51
- Revenue Growth
- SNDX N/A
- JBI N/A
- 52 Week Low
- SNDX $8.58
- JBI $5.99
- 52 Week High
- SNDX $25.07
- JBI $15.24
- Technical
- Relative Strength Index (RSI)
- SNDX 36.85
- JBI 47.64
- Support Level
- SNDX $11.00
- JBI $7.83
- Resistance Level
- SNDX $11.83
- JBI $8.85
- Average True Range (ATR)
- SNDX 0.58
- JBI 0.25
- MACD
- SNDX -0.11
- JBI -0.08
- Stochastic Oscillator
- SNDX 10.31
- JBI 13.06
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About JBI Janus International Group Inc.
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.